investor_presentation
Biogen
Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 ©2021 KARYOPHARM THERAPEUTICS INC. Virtual Investor Day December 8, 2021
1 ©2021 KARYOPHARM THERAPEUTICS INC.
Virtual Investor Day
December 8, 2021 2 ©2021 KARYOPHARM THERAPEUTICS INC. Forward -looking Statements and Other Important Information
This presentation contains forward -looking statements within themeaning ofThe Private Securities Litigation Reform Actof1995 .Such forward -looking statements include those regarding Karyopharm’s
guidance onitsexpected cash runway and2022 revenue andresearch anddevelopment expenses ;expectations andplans relating toXPOVIO oranyofitsdrug candidates, ifapproved, forthetreatment of
adult patients withrelapsed orrefractory multiple myeloma orrelapsed orrefractory diffuse large B-celllymphoma andother hematologic malignancies andsolid tumors ;commercialization ofXPOVIO oranyof
itsdrug candidates, ifapproved, andthecommercial performance ofXPOVIO ;submissions to,andthereview andpotential approval ofselinexor oranyofitsother drug candidates by,regulatory authorities,
including theCompany’s regulatory strategy, theanticipated availability ofdata tosupport such submissions, timing ofsuch submissions andactions byregulatory authorities andthepotential availability of
accelerated approval pathways ;theexpected design oftheCompany’s clinical trials ;andthetherapeutic potential ofandpotential clinical development plans forKaryopharm's drug candidates, especially
selinexor andeltanexor .Such statements aresubject tonumerous important factors, risks anduncertainties, many ofwhich arebeyond Karyopharm's control, thatmay cause actual events orresults todiffer
materially from Karyopharm's current expectations .Forexample, there canbenoguarantee thatKaryopharm willsuccessfully commercialize XPOVIO ;thatregulators willgrant confirmatory approval inthe
European Union based ontheBOSTON study inadult patients with multiple myeloma ;orthatanyofKaryopharm’s drug candidates, including selinexor andeltanexor, willsuccessfully complete necessary
clinical development phases orthat development ofany ofKaryopharm’s drug candidates willcontinue .Further, there can benoguarantee that any positive developments inthedevelopment or
commercialization ofKaryopharm’s drug candidate portfolio willresult instock price appreciation .Management’s expectations and, therefore, anyforward -looking statements inthispresentation could also be
affected byrisks anduncertainties relating toanumber ofother factors, including thefollowing :theriskthattheCOVID -19pandemic could disrupt Karyopharm’s business more severely than itcurrently
anticipates, including bynegatively impacting sales ofXPOVIO, interrupting ordelaying research and development efforts, impacting theability toprocure sufficient supply forthedevelopment and
commercialization ofselinexor orother drug candidates, delaying ongoing orplanned clinical trials, impeding theexecution ofbusiness plans, planned regulatory milestones andtimelines, orinconveniencing
Preview truncated — download the full document for the complete content.
conference
34 Pages
investor_presentation
19 Pages
Berkshire Grey
investor_presentation
Biogen